Supplemental Table 3. Complications of decitabine therapy over time by disease phase

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Complication (+rux)** | **BP** | **AP** | **HR** | **Total** |  | **Complication (-rux)** | **BP** | **AP** | **HR** | **Total** |
| **Bacterial Infection** |  |  |  |  |  | **Bacterial Infection** |  |  |  |  |
| 1 Month | 33.3% | 16.7% | 33.3% | 26.7% |  | 1 Month | 50.0% | 50.0% | 0.0% | 27.3% |
| 3 Month | 25.0% | 0.0% | 0.0% | 10.0% |  | 3 Month | 50.0% | 50.0% | 0.0% | 30.8% |
| 6 Month | 0.0% | 33.3% | 0.0% | 12.5% |  | 6 Month | 0.0% | 100.0% | 33.3% | 55.6% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 12 Month | 0.0% | 100.0% | 25.0% | 40.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 100.0% | 0.0% | 25.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 100.0% | 0.0% | 33.3% |
| **Viral Infection** |  |  |  |  |  | **Viral Infection** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 33.3% | 6.7% |  | 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 33.3% | 0.0% | 0.0% | 16.7% |  | 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Fungal Infection** |  |  |  |  |  | **Fungal Infection** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 1 Month | 33.3% | 0.0% | 0.0% | 9.1% |
| 3 Month | 25.0% | 0.0% | 0.0% | 10.0% |  | 3 Month | 50.0% | 0.0% | 0.0% | 7.7% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Arterial Thrombus** |  |  |  |  |  | **Arterial Thrombus** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Venous Thrombus** |  |  |  |  |  | **Venous Thrombus** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 25.0% | 0.0% | 10.0% |  | 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 6 Month | 0.0% | 33.3% | 16.7% | 22.2% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Hemorrhage** |  |  |  |  |  | **Hemorrhage** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 33.3% | 6.7% |  | 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 50.0% | 0.0% | 16.7% |  | 12 Month | 0.0% | 100.0% | 0.0% | 20.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |  | 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |

Rates of infection did not differ between the DEC monotherapy cohort and the DEC plus ruxolitinib cohort.